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Pulmonary Nodular Ground-Glass
Opacities in Patients With
Extrapulmonary Cancers*
What is Their Clinical Significance and How Can
We Determine Whether They Are Malignant or
Benign Lesions?
Chang Min Park, MD; Jin Mo Goo, MD; Tae Jung Kim, MD; Hyun Ju Lee, MD;
Kyung Won Lee, MD; Chang Hyun Lee, MD; Young Tae Kim, MD;
Kwang Gi Kim, PhD; Ho Yun Lee, MD; Eun-Ah Park, MD;
and Jung-Gi Im, MD
Background: The clinical significance of pulmonary nodular ground-glass opacities (NGGOs) in
patients with extrapulmonary cancers is not known, although there is an urgent need for study on
this topic. The purpose of this study, therefore, was to investigate the clinical significance of
pulmonary NGGOs in these patients, and to develop a computerized scheme to distinguish
malignant from benign NGGOs.
Methods: Fifty-nine pathologically proven pulmonary NGGOs in 34 patients with a history of
extrapulmonary cancer were studied. We reviewed the CT scan characteristics of NGGOs and the
clinical features of these patients. Artificial neural networks (ANNs) were constructed and tested
as a classifier distinguishing malignant from benign NGGOs. The performance of ANNs was
evaluated with receiver operating characteristic analysis.
Results: Twenty-eight patients (82.4%) were determined to have malignancies. Forty NGGOs
(67.8%) were diagnosed as malignancies (adenocarcinomas, 24; bronchioloalveolar carcinomas,
16). Among the rest of the NGGOs, 14 were atypical adenomatous hyperplasias, 4 were focal
fibrosis, and 1 was an inflammatory nodule. There were no cases of metastasis appearing as
NGGOs. Between malignant and benign NGGOs, there were significant differences in lesion size;
the presence of internal solid portion; the size and proportion of the internal solid portion; the
lesion margin; and the presence of bubble lucency, air bronchogram, or pleural retraction
(p < 0.05). Using these characteristics, ANNs showed excellent accuracy (z value, 0.973) in
discriminating malignant from benign NGGOs.
Conclusions: Pulmonary NGGOs in patients with extrapulmonary cancers tend to have high
malignancy rates and are very often primary lung cancers. ANNs might be a useful tool in
distinguishing malignant from benign NGGOs. (CHEST 2008; 133:1402–1409)
Key words: computer; CT scan; lung cancer; radiology diagnostic
Abbreviations: AAH  atypical adenomatous hyperplasia; ANN  artificial neural network; Az  area under the
receiver operating characteristic curve; BAC  bronchioloalveolar carcinoma; CI  confidence interval; GGO  ground-
glass opacity; NGGO  nodular ground-glass opacity; ROC  receiver operating characteristic
Pulmonary nodular ground-glass opacities (NGGOs)are defined as nodules showing a hazy opacity
without obscuring any underlying bronchial or vas-
cular structures on a high-resolution CT scan.1,2
With the popular use of CT scanning in clinical
practice and the introduction of CT scan screening
for lung cancer, pulmonary NGGOs that could not
have been detectable on plain radiography have been
discovered.3–5 In screening situations, these lesions
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all CT scan-detected pulmonary nodules. Although
several studies2,4,7–9 have reported that pulmonary
NGGOs could represent conditions such as focal
fibrosis, hemorrhage, inflammation, and atypical ad-
enomatous hyperplasia (AAH), it has been found
that pulmonary NGGOs could also strongly suggest
malignancies, such as bronchioloalveolar carcinoma
(BAC) or pulmonary adenocarcinoma, especially
when the lesions persisted during the follow-up
period.7,10–13 However, almost all of these studies
have been performed without regard to whether
patients with pulmonary NGGOs had previous or
current malignancies. It had not been known
whether those results could be directly applied to
patients with previous or current extrapulmonary
cancers or if we could consider NGGOs in these
patients as BACs or pulmonary adenocarcinomas
rather than metastasis. However, since CT scan-
ning has become a routine tool in diagnosing
malignancies and monitoring treatment response
as well as disease recurrence in cancer patients,
pulmonary NGGOs are not uncommonly discov-
ered even in patients with previous or current
extrapulmonary cancers. To the best of our knowl-
edge, although there has been an urgent need for
a study on the clinicopathologic significance of
NGGOs in patients with extrapulmonary cancers,
there have been none, aside from only a few case
reports.14,15
Therefore, the purpose of this study was to inves-
tigate the clinicopathologic significance of NGGOs
in patients with extrapulmonary cancers. We also
aimed to investigate the clinical and CT scan char-
acteristics associated with malignancy and to develop
a computerized scheme to distinguish malignant
from benign NGGOs in these patients.
Materials and Methods
This study was approved by the institutional review board of
the hospitals involved; the requirement for patients’ informed
consent was waived in this retrospective study.
Study Subjects
Between January 2002 and March 2007, two radiologists
(H.Y.L. and H.J.L.) retrospectively collected cases of pulmonary
NGGOs in patients with extrapulmonary cancers from two
tertiary referral hospitals (Seoul National University Hospital and
Seoul National University Bundang Hospital) using electronic
medical records and the radiology information systems of the
hospitals. We included cases that met the following criteria: (1)
pulmonary NGGOs were found in patients with previous or
current malignancies other than lung cancer; (2) patients had at
least one series of thin-section chest CT scans showing an
NGGO; (3) the NGGO was a focal ground-glass opacity (GGO)
with nodular features  3 cm in size; and (4) the nodule was
confirmed pathologically with meticulous histologic evaluation.
In the end, 59 nodules in 34 patients (11 men and 23 women;
mean [ SD] age, 59.7  10.7 years) met the inclusion criteria.
Thirty-seven of these 59 NGGOs did not show internal solid
portions, and the remaining 22 NGGOs had internal solid
portions. The histologic diagnosis of the pulmonary NGGO was
confirmed via wedge resection (n  16) and lobectomy (n  43).
The median time interval between the diagnosis of primary
extrapulmonary cancer and the pulmonary NGGOs was 24.6
months (range, 0 to 13 years). Table 1 shows the sites and
histologies of primary extrapulmonary malignancies in the study
population. One patient had synchronous breast cancer and
thyroid cancer. All patients (n  34) received appropriate treat-
ment as recommended by the clinicians.
CT Scan Examinations
Three patients underwent initial thin-section CT scans, and the
remaining 31 patients underwent initial thick-section CT scans.
All patients (n  34) underwent at least one thin-section CT scan
examination during follow-up, which was performed for the
further characterization of pulmonary NGGOs. The mean CT
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Table 1—Primary Extrapulmonary Malignancies






Cancer (No. of Patients)
NGGOs,
Total No.
Breast* 10 Ductal adenocarcinoma (9),
lobular adenocarcinoma (1)
12
Thyroid* 6 Papillary carcinoma (6) 14
Stomach 4 Adenocarcinoma (4) 13
Bladder 3 Transitional cell carcinoma (3) 6
Liver 3 Hepatocellular carcinoma (3) 3
Prostate 2 Adenocarcinoma (2) 3
Thymus 2 Thymic carcinoma (2) 2
Uterine cervix 1 Squamous cell carcinoma (1) 3
Colon 1 Adenocarcinoma (1) 1
Kidney 1 Renal cell carcinoma (1) 1
Skin melanoma 1 Melanoma (1) 1
Bone 1 Chondrosarcoma (1) 1
Total 34 59
*One pulmonary NGGO was found in a patient with synchronous
thyroid cancer and breast cancer.
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scan follow-up period was 128.8  184.6 days (range, 5 to 870
days). CT scanning was performed using various CT scanners
(Light Speed Ultra; GE Medical Systems; Milwaukee, WI;
Sensation-16; Siemens Medical Systems; Erlangen, Germany;
and MX-8000, Brilliance-64; Phillips Medical Systems; Amster-
dam, the Netherlands). CT scanning was performed at 120 kVp,
50 to 200 mA, and at a pitch of 0.875 to 1.5. Images were
reconstructed using high-frequency algorithms with a slice thick-
ness of 1 to 5 mm. Thin-section CT scan images referred to
images with slice thicknesses of  1.25 mm, and thick-section CT
scan images referred to images with slice thicknesses of  1.25
mm. The mean time interval between the last thin-section CT
scan and surgical resection of the NGGO was 14.6  13.4 days
(range, 0 to 48 days).
Evaluation of Clinical and CT Scan Characteristics of NGGOs
The clinical data for patients with NGGOs were recorded by
one radiologist (E.A.P.). The following demographic and clinico-
pathologic data were recorded: (1) age and sex; (2) smoking
history (ie, never-smoker or ever smoker) and smoking amount;
(3) mode used for detection of the lesion (ie, during workup for
primary cancer or during symptom evaluation); and (4) informa-
tion regarding the primary extrapulmonary cancer, such as site,
pathologic diagnosis, or TNM stage of the disease. If a patient
had more than one primary extrapulmonary cancer, the diagnosis
date of the most recently diagnosed cancer was recorded. We
categorized the TNM stage of primary extrapulmonary cancers as
limited disease (stage 1 or 2) or advanced disease (stage 3 or 4).
All thin-section CT scan images were reviewed by three chest
radiologists (C.M.P., T.J.K., and J.M.G., with 4, 5, and 12 years,
respectively, of experience in reading chest CT scans), who were
blinded to the clinical information. Decisions on thin-section CT
scan findings were reached through consensus. When patients
had undergone more than one follow-up thin-section CT scan
examination prior to surgical resection, we chose the last thin-
section CT scan examination for the evaluation. Thin-section CT
scan findings for each NGGO were analyzed for the following: (1)
lesion location; (2) lesion size; (3) the presence of internal solid
portion within the NGGO; (4) the size and proportion of internal
solid lesion, if any; (5) lesion multiplicity (eg, solitary or multiple);
(6) shape (eg, round or oval, and polygonal); (7) margin (eg,
well-defined or ill-defined; smooth or lobulated); and (8) the
presence of pleural retraction, air bronchogram, or bubble
lucency. One radiologist (C.M.P.) recorded the average product
of the height and width of a lesion to determine lesion size.
Statistical Analysis
The relationship between the final diagnosis of NGGOs and
the clinical and CT scan features of NGGOs were analyzed using
the Pearson 2 test, the Fisher exact test, or the independent
sample t test, as appropriate. Statistical analyses were performed
using a statistical software package (SPSS, version 13.0 for
Windows; SPSS; Chicago, IL). A p value of  0.05 was consid-
ered to indicate a significant difference.
Artificial neural networks (ANNs) with multilayer perceptrons
were constructed and tested as a computerized scheme to predict
the malignancy probability of each NGGO using commercially
available software (NeuroSolution, version 5.0; NeuroDimension;
Gainesville, FL).16 The ANNs consisted of one input layer, one
hidden layer, and one output layer. Statistically significant clinical
features of patients and CT scan features of each NGGO were
used as input data for the ANNs. All input data with numeric
values were normalized to a range of 0 to 1.0, and the other input
data were used as symbolic values. A nonlinear sigmoid function
was used as a transfer function in the hidden layers and output
layers of the networks. The hidden layer was connected to an
output layer of a single neuron producing a normalized value
(range, 0 to 1.0), which could be regarded as representing the
malignancy probability of each NGGO (0, benign; 1, malignant).
The ANNs were trained until the mean training error of the
network decreased to below 0.01, meaning that if the output of
the networks was not within 0.01 of the target output, it was
considered to be incorrect. During the training process, the
connection weights between the neurons were adjusted by using
a back-propagation updating algorithm to minimize the output
error. The maximum number of iterations was limited to 1,000.
The ANNs were trained and tested using the leave-one-out
method because of the limited data set that was available for this
study. In this method, all NGGOs except one were used to train
the ANNs, which in turn were applied to the independent lesion
that was left out for testing. This procedure was repeated so that
each NGGO was included in the testing.
The predictive performance of the ANNs was evaluated using
binormal receiver operating characteristic (ROC) analysis using
appropriate software (MedCalc, version 7.4; MedCalc Software;
Mariakerke, Belgium).17 The area under the ROC curve (Az)
value was used as an index of the performance of ANNs in
discriminating malignant from benign NGGOs. We calculated
the sensitivity and specificity of the ANNs for the differentiation
of malignant from benign NGGOs with an optimal ANN output
level that was defined as the intersection of the ROC curve with
the second bisectrix, at which point sensitivity balanced with
specificity.18
Results
Histopathologic Diagnosis and Clinical Significance
of NGGOs
The results of the histologic diagnosis of 59 NGGOs
in 34 patients with extrapulmonary cancers were as
follows: 24 pulmonary adenocarcinomas (Fig 1); 16
BACs (Fig 2); 14 AAHs (Fig 3); 4 focal fibroses; and
1 chronic granulomatous inflammation. None of
these 59 NGGOs constituted metastasis from pri-
mary cancers, although eight solid nodules in our
study were pathologically confirmed as metastasis in
three patients. Table 2 summarizes the diagnostic
results for the NGGOs based on primary extrapul-
monary cancers. Twenty-eight of 34 patients (82.4%;
95% confidence interval [CI], 69.6 to 95.2%) were
determined to have malignancies, and 6 patients
(17.6%; 95% CI, 4.8 to 30.4%) had benign NGGOs.
Forty lesions (67.8%; 95% CI, 55.9 to 79.7%) were
diagnosed as malignancies.
Clinical and CT Scan Characteristics of NGGOs
Regarding the clinical characteristics of the 34
patients (Table 3), there was no significant differ-
ence between patients with malignant NGGOs and
those with benign lesions. Although the frequency of
malignancy was higher in women or never-smokers
than in men or smokers, statistical significance was
not found between malignant and benign NGGOs
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with regard to patient sex (p  0.178) or smoking
history (p  0.315). There was no significant differ-
ence in the other clinical characteristics such as
smoking amount, mode used for detection of the
lesion, and stage of primary extrapulmonary cancer.
Thin-section CT scan features of NGGOs are
summarized in Table 4. The right upper lobe was the
most common location of NGGOs; however, the
difference was not significant (p  0.951). The mean
size of NGGOs in the present study was 11.2  6.9
mm (range, 3 to 30 mm), and the sizes of the
malignant NGGOs (mean, 13.18  7.28 mm) were
significantly larger than those of the benign lesions
(mean, 6.86  3.26 mm; p  0.01). Most benign
NGGOs were  10 mm in diameter. However, of all
NGGOs  10 mm in size in our study, 50% (16 of 32
NGGOs) were malignancies. With respect to the
presence of an internal solid portion within the
NGGO, there was significant difference between
malignant and benign NGGOs (p  0.05). The mean
size and proportion of the internal solid components
in the case of malignant NGGOs (4.38  5.92 mm
and 26.0  30.76%, respectively) were greater than
those of benign lesions (0.37  1.61 mm and
3.7  16%, respectively; p  0.01). The morpho-
logic characteristics of nodules such as lesion margin,
and the presence of bubble lucency, air bron-
chogram, or pleural retraction were significantly
different between malignant and benign NGGOs
(p  0.05) [Table 4].
Performance of ANNs in Discriminating Malignant
From Benign NGGOs
Lesion size, the presence of internal solid portion,
the size of internal solid portion, the lesion margin,
and the presence of bubble lucency, air bron-
chogram, or pleural retraction, which were significantly
different between malignant and benign NGGOs
in the univariate analysis, were used as input param-
eters for the ANNs. The ROC curve of ANNs for
distinguishing malignant from benign NGGOs is
illustrated in Figure 4. The performance of the
ANNs occurred with multilayer perceptrons in our
study, and the Az value was 0.973 (95% CI, 0.903 to
0.996). With an ANN output level of 0.57, the
sensitivity and specificity of the ANNs for the differ-
Figure 1. Adenocarcinoma in a 51-year-old asymptomatic
woman with previous breast cancer. The transverse thin-section
CT scan shows a 14-mm GGO nodule with internal solid part in
the right lower lobe. This lesion was confirmed as pulmonary
adenocarcinoma with a mixed BAC pattern.
Figure 2. BAC in a 45-year-old woman with current hepatocel-
luar carcinoma in the liver. Top: transverse thin-section CT scan
shows a 6-mm GGO nodule without an internal solid part in the
right upper lobe. This lesion was confirmed as BAC of the lung.
Bottom: a well-defined solid nodule is seen in the right upper
lobe at the 2-cm caudal to the top image. This lesion was
confirmed as metastatic hepatocellular carcinoma.
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entiation of malignant from benign NGGOs were
97.5% (95% CI, 86.8 to 99.6%) and 93.5% (95% CI,
78.5 to 99.0%), respectively.
Discussion
To our knowledge, this is the first study to docu-
ment the clinical significance of pulmonary NGGOs
in patients with extrapulmonary cancers. The major
findings of this study were as follows: (1) the malig-
nancy rate for NGGOs in patients with extrapulmo-
nary cancers was high (patients, 82.4%; nodules,
67.8%); (2) all malignant NGGOs were primary lung
cancers; (3) the CT scan characteristics of NGGOs
were useful in discriminating malignant NGGOs
from benign NGGOs, and CT scan findings showed
that there was a significant difference in lesion size,
the presence of an internal solid portion within the
NGGO, the size and proportion of the internal solid
component, the lesion margin, and the presence of
bubble lucency, air bronchogram, or pleural retrac-
tion; and (4) ANNs showed excellent accuracy in the
discrimination of malignant NGGOs from benign
NGGOs.
The malignancy rate of NGGOs in patients with
extrapulmonary cancers in our study was 82.4% for
patients and 67.8% for nodules. According to several
more recent studies19–21 that have been conducted
in the CT scan era, the malignancy rates of
noncalcified solid nodules in patients with ex-
trapulmonary cancers ranged from approximately
42 to 80.7%, and the rates of lung cancers ranged
from 21.2 to 50.3%. Considering that none of the
NGGOs in our study were metastases, the malignancy
rate of the NGGOs was very high. The high malignancy
rate of the NGGOs, particularly NGGOs with internal
solid components, has already been reported in
several other studies.1,7,22 In one study, Henschke
et al1 reported a higher malignancy rate for the
NGGOs than for solid nodules, even though the
study was performed in the screening setting. In
another study, Nakata et al7 reported that all of
their persistent NGGOs were neoplasms and the
malignancy rate of NGGOs was 79.1%. Kim et al22
also reported that in their study 75% of the
persistent NGGOs were malignancies. These re-
sults were consistent with those of our study,
although their study populations were composed













Breast† 10 3 (30) 7 (70) 12 4 (33.3) 8 (66.7)
Thyroid† 6 1 (16.7) 5 (83.3) 14 8 (57.1) 6 (42.9)
Stomach 4 1 (25) 3 (75) 13 5 (38.5) 8 (61.5)
Bladder 3 0 3 (100) 6 0 6 (100)
Liver 3 1 (33.3) 2 (66.7) 3 1 (33.3) 2 (66.7)
Prostate 2 0 2 (100) 3 0 3 (100)
Thymus 2 2 (100) 0 2 2 (100) 0
Uterine cervix 1 0 1 (100) 3 1 (33.3) 2 (66.7)
Colon 1 0 1 (100) 1 0 1 (100)
Kidney 1 0 1 (100) 1 0 1 (100)
Skin melanoma 1 0 1 (100) 1 0 1 (100)
Bone 1 0 1 (100) 1 0 1 (100)
Total 34 7 27 59 20 39
*Values are given as No. (%), unless otherwise indicated.
†One benign NGGO was found in patient with synchronous thyroid cancer and breast cancer.
Figure 3. AAH in a 64-year-old asymptomatic woman with
previous thyroid cancer. Transverse thin-section CT scan shows a
7-mm GGO nodule without an internal solid part in the left
upper lobe.
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of asymptomatic screening individuals and pa-
tients with other diseases.7,22
In the present study, all malignant NGGOs were
primary lung cancers. It has been reported in
several studies1,4,7,10,11 that NGGOs have a high
probability of being BACs or pulmonary adenocar-
cinomas. However, those studies have been per-
formed without regard to whether patients had
previous or concurrent cancers. This result in our
study might be helpful in determining whether an
NGGO is benign, a primary lung cancer, or me-
tastasis. Indeed, some cases of metastatic tumors
showing NGGOs have been reported;15,23 how-
ever, NGGOs representing metastasis seem to be
very rare. Gaeta et al24 reported that 2 of 65
patients in their study with proven lung metastasis
from adenocarcinoma of the GI tract showed
NGGOs. However, the frequency of metastasis
showing NGGOs may have been overestimated in
their study because they excluded pathologically
unproven round pulmonary nodules. Metastasis
from malignant melanoma could also manifest as
NGGOs in the lung.15 The metastatic lesions from
malignant melanomas were presumed to come to
the alveoli via the bloodstream and spread beneath
the alveolar epithelium.15 However, even though it
might be possible that metastatic tumors manifest as
NGGOs in the lung, it is not common for us to
encounter such metastatic nodules showing NGGOs.
In this context, Fraser et al25 recommended that we
should consider the possibility of early pulmonary
adenocarcinoma or BAC when we come across
persistent NGGOs in the lung.
There was a significant difference in lesion size,
the presence of an internal solid portion within the
NGGO, the size and proportion of the internal
solid component, the lesion margin, and the presence
of bubble lucency, air bronchogram, or pleural retrac-
tion between malignant and benign NGGOs.
In our study, malignant NGGOs were significantly
larger than benign NGGOs. This result might be
explained by the fact that the majority of benign
NGGOs were AAHs, and all malignancies were
BACs or pulmonary adenocarcinomas in our study. A
couple of studies7,11 have also reported that AAH
was smaller than BAC or pulmonary adenocarci-
noma and was not  1 cm in size. In that context,
1 cm in diameter has been suggested as a criterion
for discriminating BAC from AAH.7 It has also been
reported that NGGOs containing solid components
had higher malignancy rates than those without solid
components.1,4,7,13
ANNs showed excellent performance in distin-
guishing between malignant and benign NGGOs.
This computerized scheme might be a useful tool for
that purpose, in that, according to one study,26 the
diagnostic yield of CT scan-guided aspiration biopsy
was not so good in NGGOs, even when the sizes of
the NGGOs were between 10 and 15 mm in diam-
eter. However, the performance of the ANNs in
discriminating malignant from benign NGGOs
should be tested and confirmed in an independent
group of subjects before the ANNs are applied to the
general population.
Our study has several limitations. First, due to the
retrospective nature of our study, CT scan examina-
tions were not carried out using the same protocol. It
is possible that some NGGOs could have been
undetected since patients underwent only initial
thick-section CT scans. Second, the number of pa-
Table 3—Clinical Features of Patients With NGGOs and Extrapulmonary Cancers*
Characteristics
Patients With Benign Lesion
(n  7)
Patients With Malignant Lesion
(n  27) p Value
Age, yr† 63.0  10.39 58.78  10.74 0.358†
Sex
Male 4 (57.14) 7 (25.93) 0.178‡
Female 3 (42.86) 20 (74.07)
Smoking history
Never-smoker 4 (57.14) 22 (81.48) 0.315‡
Ever smoker 3 (42.86) 5 (18.52)
Smoking amount,† pack-yr 14.57  22.05 8.15  19.22 0.450†
Mode of detection
During workup for primary cancer 7 (100) 26 (96.29) 1.00‡
During symptom evaluation 0 1 (3.71)
Stage of primary cancer
Limited disease (I or II) 7 (100) 20 (74.07) 0.300‡
Advanced disease (III or IV) 0 7 (25.93)
*Values are given as the mean  SD or No. (%), unless otherwise indicated.
†Independent sample t test.
‡Fisher exact test.
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tients in our study was small; therefore, it could be
difficult to state confidently a malignancy rate or a
rate of metastasis that manifests as NGGOs. Third,
we only included cases that were confirmed with a
pathologic specimen; therefore, we may have omit-
ted many malignancies that were not resected and
may have only included lesions with a high probabil-
ity of malignancy. In addition, many cancer patients
did not undergo lung nodule resection if the risk of
the procedure exceeded the benefits of the proce-
dure, possibly leading to bias. Thus, further study is
necessary in a larger number of patients with a
prospective study design. Despite these limita-
tions, however, we are confident that this study
will be helpful in clinical practice and in the
decision making of clinicians and radiologists
when NGGOs are encountered in patients with
extrapulmonary cancers.
In summary, NGGOs in patients with extrapulmo-
nary cancers tend to have a high malignancy rate and
are very often primary lung cancers. ANNs with
Figure 4. A ROC curve of ANNs with multilayer perceptrons
for distinguishing malignancy from benignity is shown. In the
performance of the ANNs, the Az value was 0.973. The intersec-
tion of the curve with the second bisectrix at which sensitivity
balanced specificity was used to determine the optimal threshold
to discriminate malignant NGGOs from benign NGGOs.
Table 4—CT Scan Features of NGGOs in Patients With Extrapulmonary Cancers*
Characteristics Benign Lesion (n  20) Malignant Lesion (n  39) p Value
Lesion location
RUL (n  24) 8 (40) 16 (41) 0.951†
RML (n  11) 3 (15) 8 (20.5)
RLL (n  14) 5 (25) 9 (23.1)
LUL (n  6) 2 (10) 4 (10.3)
LLL (n  4) 2 (10) 2 (5.1)
Lesion size, mm 6.86  3.26 13.18  7.28  0.01‡
Presence of internal solid portion
Yes (n  22) 3 (15) 19 (48.7)  0.05†
No (n  37) 17 (85) 20 (51.3)
Internal solid component
mm 0.37  1.61 4.38  5.92  0.01‡
% 3.7  16 26.0  30.76  0.01‡
Lesion multiplicity
Solitary (n  22) 6 (30) 16 (41) 0.407†
Multiple (n  37) 14 (70) 23 (59)
Shape of lesion
Round or oval (n  23) 20 (100) 33 (84.6) 0.087§
Polygonal (n  6) 0 6 (15.4)
Border of lesion
Well defined (n  58) 19 (95) 39 (100) 0.339§
Ill-defined (n  1) 1 (5) 0
Margin of lesion
Smooth (n  51) 20 (100) 31 (79.5)  0.05§
Lobulated (n  8) 0 8 (20.5)
Bubble lucency, air bronchogram,
pleural retraction
Yes (n  18) 1 (5) 17 (43.6)  0.01§
No (n  41) 19 (95) 22 (56.4)
*Values are given as No. of nodules (%) or mean  SD, unless otherwise indicated. RUL  right upper lobe; RML  right middle lobe;
RLL  right lower lobe; LUL  left upper lobe; LLL  left lower lobe.
†Pearson 2 test.
‡Independent sample t test.
§Fisher exact test.
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multilayer perceptrons may be a useful tool in
distinguishing malignancies from benign lesions.
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